List of Excipients in Branded Drug NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

« Back to Dashboard

Generic Drugs Containing NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

Company	Ingredient	NDC	Excipient
MWI/VetOne	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	13985-016	MINERAL OIL
MWI/VetOne	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	13985-016	PETROLATUM
Bausch & Lomb Incorporated	neomycin sulfate and polymyxin b sulfate, bacitracin zinc and hydrocortisone	24208-785	MINERAL OIL

What are the Most Frequently-Used Excipients in NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE?

# Of NDCs	Excipient
2	MINERAL OIL
2	PETROLATUM

Excipient Strategy and Commercial Opportunities for Neomycin, Polymyxin B, Bacitracin Zinc and Hydrocortisone

Last updated: August 31, 2026

The established ophthalmic ointment containing neomycin sulfate, polymyxin B sulfate, bacitracin zinc and hydrocortisone is a mature, multisource product. Its commercial value is driven less by active-ingredient patent protection than by formulation control, ophthalmic manufacturing capability, supply reliability, packaging, regulatory execution and channel access. The core excipient platform is typically an anhydrous petrolatum and mineral-oil base, which supports preservative-free packaging and long shelf life but creates viscosity, dose-uniformity and patient-acceptability constraints.

The strongest commercial opportunities are differentiated generic products, contract manufacturing, private-label supply, preservative-free ophthalmic ointments, improved dispensing systems and manufacturing platforms that reduce batch variability.

What is the established formulation for this ophthalmic combination?

The relevant product is an ophthalmic ointment containing four active components:

Active ingredient	Pharmacologic role	Formulation implication
Neomycin sulfate	Aminoglycoside antibacterial	Requires uniform dispersion and control of sulfate salt variability
Polymyxin B sulfate	Antibacterial	Potency is measured in units and depends on microbiological assay control
Bacitracin zinc	Polypeptide antibacterial	Requires control of zinc-associated material and potency
Hydrocortisone	Corticosteroid anti-inflammatory	Requires chemical stability and uniform distribution in the ointment base

The established product category is generally anhydrous and uses white petrolatum with mineral oil or a comparable ophthalmic hydrocarbon base. The base avoids an aqueous phase and typically does not require a conventional antimicrobial preservative. Product labeling warns against prolonged use and use in certain untreated ocular infections because the corticosteroid can suppress inflammation while worsening or masking infection [1].

The dosage form is usually supplied in a sterile ophthalmic tube. The tube, cap, filling process and terminal or aseptic sterilization strategy are part of the product's quality profile, not merely packaging choices.

What excipients are most commercially suitable?

White petrolatum and mineral oil

White petrolatum provides the structural matrix. Mineral oil adjusts consistency, spreadability and extrusion force. This combination is commercially attractive because it is well established in ophthalmic ointments and has a long manufacturing history.

Key development variables include:

• Petrolatum grade and hydrocarbon profile
• Mineral-oil viscosity
• Softening point
• Ointment yield value
• Extrusion force through the tube orifice
• Residence time on the ocular surface
• Drug sedimentation or agglomeration
• Container-closure compatibility

A higher-viscosity base may improve ocular residence time but can produce blurred vision, poor patient acceptance and inconsistent dose delivery. A softer base improves dispensing but can increase leakage, phase migration or heat sensitivity.

Alternative hydrocarbon systems

A developer may optimize the ratio of petrolatum to liquid paraffin, add microcrystalline wax or use a different pharmaceutical-grade hydrocarbon structure. These changes can create a meaningful product-performance distinction without altering the active ingredients.

Potential advantages include:

• Lower extrusion force
• More consistent ribbon formation
• Reduced separation during storage
• Improved low-temperature performance
• Better tube emptying
• More predictable ocular residence time

These changes also create regulatory risk if they alter release, ocular tolerability or drug distribution. A formulation that appears materially different from the reference product may require stronger comparative characterization and may complicate an ANDA equivalence argument.

Polyethylene glycol and water-miscible bases

Polyethylene glycol ointment systems can offer cleaner washout and different spreadability. They also create more development variables, including ocular irritation, hygroscopicity, active solubility, water uptake and preservative requirements.

For this four-active combination, a PEG-based system is less commercially efficient than a hydrocarbon base unless it provides a clear benefit. The active ingredients have different physical and chemical properties, and the formulation must maintain uniformity across antibacterial salts and the corticosteroid. A PEG platform may be more defensible as a differentiated formulation but carries higher development and regulatory costs.

Emulsion or gel systems

An emulsion, gel or in situ gelling system could improve cosmetic acceptability and reduce persistent blurring. It would also introduce water activity, preservative selection, microbial-control requirements and more complex stability testing.

These platforms are more suitable for a reformulation strategy than for a low-cost generic strategy. They may support a lifecycle product, but they are unlikely to be the fastest route to market.

How should an excipient strategy address ophthalmic quality risks?

FDA ophthalmic guidance places emphasis on sterility, particulate control, container-closure integrity, manufacturing controls and product quality attributes that can affect ocular safety [2]. USP General Chapter <771> covers ophthalmic products and related quality considerations [3].

Sterility and microbial control

An anhydrous ointment does not eliminate the need for sterile manufacturing. The product must control bioburden, maintain sterility and prevent contamination during filling and use.

A suitable strategy includes:

1. Qualified pharmaceutical-grade excipients.
2. Controlled heating and compounding conditions.
3. Validated filtration or sterilization where applicable.
4. Aseptic filling or a validated terminal process.
5. Container-closure integrity testing.
6. Tight control of environmental monitoring and operator intervention.

The formulation should avoid unnecessary aqueous components. Water can increase microbial risk, change active stability and complicate preservative effectiveness.

Uniformity of active ingredients

The four actives do not have identical assay characteristics. Neomycin and polymyxin B are sulfate salts, bacitracin is a zinc-associated material, and hydrocortisone is a corticosteroid with different particle and solubility behavior.

Critical process parameters include:

• Order of addition
• Mixing energy
• Temperature profile
• Wetting of active powders
• Particle-size distribution
• Deagglomeration
• Hold time before filling
• Homogeneity sampling design

A common failure mode is acceptable assay averages with inadequate content uniformity. The risk is highest when low-dose hydrocortisone is distributed through a large hydrocarbon matrix.

Particulate and ocular tolerability control

Particulate matter is a central ophthalmic concern. Excipients and active ingredients should be screened for visible and subvisible particles, foreign matter and incompatibility with the tube.

The commercial product should target:

• Low visible particulate burden
• Consistent ointment texture
• Minimal grittiness
• No phase separation
• No tube corrosion or extractables concern
• Acceptable ocular comfort after application

Hydrocarbon bases are generally favorable for chemical simplicity, but they can produce an unpleasant visual experience. Patient acceptance may improve through lower viscosity and a narrower, more consistent ribbon.

What formulation patents protect this product category?

The core combination is based on old active ingredients and a long-established ophthalmic ointment platform. Broad composition-of-matter protection for neomycin, polymyxin B, bacitracin and hydrocortisone is not the principal commercial barrier.

The relevant intellectual-property categories are more likely to be:

IP category	Commercial relevance
Specific excipient ratios	May protect viscosity, stability or dispensing behavior
Sterile manufacturing processes	Can protect process controls, but enforcement value depends on claim scope
Tube and applicator design	May support device differentiation
Particle-size or dispersion controls	Can protect product uniformity and release characteristics
Method-of-use claims	Potentially relevant to specific ocular indications
Packaging and dose-delivery systems	May create device or combination-product protection
Reformulated aqueous or gel products	More likely to support new patent filings

An applicant should search the relevant Orange Book-listed patents for the reference product, current FDA labels, assignment records and patent-family status before selecting a filing pathway. The Orange Book identifies approved drug products, therapeutic equivalence information and, where applicable, listed patents and exclusivity [4].

For a mature generic product, the principal patent risk is usually residual formulation or use claims rather than active-ingredient claims. A Paragraph IV certification may be relevant if a listed patent remains active and blocks the reference product. If no unexpired listed patent applies, a Paragraph III or Paragraph II pathway may be more appropriate, depending on the Orange Book record and application facts.

When does this product lose exclusivity, and what is the generic-entry risk?

The active ingredients and the conventional ointment platform are old. The market therefore generally behaves as a generic or multisource opportunity rather than a new chemical entity opportunity.

Exclusivity profile

Protection type	Likely strategic significance
New chemical entity exclusivity	Not relevant to these established actives
Orphan exclusivity	Not relevant to the standard ophthalmic product
Biosimilar exclusivity	Not relevant because the product is not a biologic
Pediatric exclusivity	Only relevant if separately granted for a specific product
Formulation exclusivity	Possible for a newly approved differentiated product
Listed patent exclusivity	Must be checked against current Orange Book records
Regulatory exclusivity for a new dosage form	Possible but fact-specific

Generic entry risk is high where the product is supplied as a conventional ointment with familiar excipients and no significant remaining patent barrier. Entry risk is lower where the incumbent has:

• A difficult-to-reproduce sterile process
• Strong physician or hospital contracts
• Reliable shortage performance
• An approved device configuration
• A differentiated tube or applicator
• A defensible formulation patent
• Exclusive supply arrangements for a critical raw material

What is the FDA regulatory status of the combination?

This is an FDA-regulated ophthalmic drug product. A conventional generic version would generally be developed through the ANDA pathway if it can demonstrate pharmaceutical equivalence and bioequivalence or other applicable equivalence requirements to the reference product.

Key regulatory issues include:

• Same active ingredients
• Same dosage form
• Same route of administration
• Comparable strength
• Pharmaceutical equivalence
• Sterility assurance
• Inactive-ingredient suitability for ophthalmic use
• Container-closure compatibility
• Drug-product stability
• Manufacturing-site readiness

Ophthalmic ointments may present distinctive bioequivalence and product-performance questions because the drug is distributed in a semisolid matrix rather than an aqueous solution. The applicant should characterize rheology, particle distribution, assay, impurities, release behavior and ocular-surface performance. FDA product-specific guidance, when available, should govern the development plan [2].

The label also creates commercial constraints. The presence of hydrocortisone limits chronic-use positioning and may narrow the patient population relative to antibiotic-only ophthalmic products. Promotional claims must remain aligned with the approved indications and warnings.

What commercial opportunities exist for excipient differentiation?

Low-cost ANDA strategy

The lowest-risk route is a formulation that closely follows the reference product's established hydrocarbon base. The objective is cost, supply reliability and equivalence rather than visible differentiation.

Commercial advantages:

• Lower development burden
• Familiar excipient safety profile
• Easier manufacturing transfer
• Lower COGS
• Broad wholesaler compatibility
• Stronger substitution potential

The weakness is price competition. Multiple approved suppliers can rapidly compress margins.

Premium generic strategy

A premium generic can emphasize dispensing and patient experience rather than new pharmacology. Relevant attributes include:

• Lower extrusion force
• More consistent ribbon size
• Reduced leakage
• Better low-temperature handling
• Improved tube emptying
• Lower perceived grittiness
• Unit-dose or smaller-volume packaging

These benefits must be measurable and clinically acceptable. A device or packaging patent may support differentiation, but the product must remain economically viable for pharmacy and institutional purchasing.

Contract manufacturing and private label

Sterile ophthalmic ointment capability is valuable to companies that lack their own aseptic filling infrastructure. Contract manufacturers can offer:

• Formulation development
• Scale-up
• Sterile filling
• Tube and carton sourcing
• Stability programs
• ANDA support
• Private-label supply
• Shortage-response manufacturing

A manufacturer with validated hydrocarbon ointment processes can serve several ophthalmic products using a common platform. The four-active combination can function as an anchor product for a broader ophthalmic portfolio.

Hospital and institutional supply

Hospitals, clinics and government buyers value supply continuity, predictable pricing and approved therapeutic equivalence. The product may be commercially attractive during shortages or supplier withdrawals.

The most defensible institutional proposition is not a novel excipient. It is:

• Reliable fill-finish capacity
• Dual-source raw materials
• Validated backup packaging
• Rapid batch release
• Consistent national distribution
• Low back-order frequency

Geographic expansion

The United States is likely to have substantial generic competition. Other markets may offer opportunities where ophthalmic antibiotic-steroid combinations are available through branded generics, tender systems or local licensing.

Geographic barriers include:

• Country-specific registration requirements
• Different reference products
• Local sterility expectations
• Import controls for antibiotics
• Pharmacopoeial differences
• Local GMP inspections
• Reimbursement and tender pricing

A common formulation can reduce development cost across markets, but the label, device, pack size and regulatory dossier may require regional adaptation.

How strong is the patent estate compared with regulatory and manufacturing barriers?

The patent estate for the conventional combination is likely weaker than the operational barrier. The strongest practical barriers are:

1. Sterile ophthalmic manufacturing.
2. Consistent dispersion of four active ingredients.
3. Tube compatibility and closure integrity.
4. Stability across the proposed shelf life.
5. Low-cost commercial scale-up.
6. FDA inspection readiness.
7. Reliable supply of polymyxin B and bacitracin materials.
8. Market access through wholesalers and institutional contracts.

A new patent may improve defensibility if it covers a genuinely improved ointment, delivery system or manufacturing process. Patent value will depend on whether the claims distinguish the product from the established petrolatum-based presentation and whether a competitor can design around them without losing equivalence or performance.

Which companies are likely to challenge or compete in this market?

Competition is most likely from:

• Established generic ophthalmic manufacturers
• Branded-generic companies
• Sterile contract manufacturers
• Specialty ophthalmology companies
• Private-label pharmaceutical distributors
• Regional suppliers with hospital contracts

The most exposed incumbent is a company relying on a single manufacturing site, a narrow product presentation or a premium price without a clear dispensing advantage. The strongest challenger is likely to be a supplier with existing sterile ophthalmic infrastructure and a broad hospital or retail distribution network.

What revenue exposure and launch scenarios should investors model?

A commercial model should use product-specific assumptions rather than extrapolating from total ophthalmic-antibiotic sales.

Base-case generic launch

• Launch after ANDA approval and commercial inventory build
• Rapid price compression
• Moderate retail substitution
• Low differentiation
• Margin dependent on manufacturing efficiency

Shortage-driven launch

• Faster uptake if incumbent supply is constrained
• Higher initial net price
• Greater buyer sensitivity to delivery reliability
• Risk of volume decline when supply normalizes

Differentiated-device launch

• Higher development and packaging costs
• Slower formulary and channel adoption
• Potentially better price retention
• Added device, human-factors and combination-product considerations

Private-label launch

• Lower commercial acquisition cost
• Lower brand equity
• Greater dependence on distributor contracts
• Potentially predictable volume under tender or institutional agreements

The most important revenue variables are approved supplier count, wholesaler access, shortage status, reimbursement, manufacturing yield, tube cost, active-ingredient cost and the ability to maintain supply during competitor disruptions.

Key Takeaways

• The conventional product is primarily a generic and manufacturing opportunity, not an active-ingredient patent opportunity.
• White petrolatum and mineral oil remain the lowest-risk excipient platform for an ophthalmic ointment.
• The principal technical risks are sterility, active uniformity, rheology, particulate control and tube performance.
• A close-to-reference formulation offers the fastest path to an ANDA but faces price competition.
• Commercial differentiation is more credible through dispensing performance, packaging, supply reliability and sterile manufacturing than through unproven excipient changes.
• Paragraph IV risk depends on current Orange Book listings and any surviving formulation or method-of-use patents.
• Biosimilar competition does not apply because the product is a conventional small-molecule combination.
• Contract manufacturing, private label, hospital supply and shortage-response capacity are the most actionable commercial opportunities.
• A new patent has value only if it protects a measurable formulation, delivery or process improvement that competitors cannot easily design around.

FAQs

Is a preservative required in neomycin-polymyxin-bacitracin-hydrocortisone ophthalmic ointment?

Usually not when the product is an anhydrous sterile ointment supplied in a suitable single-use or controlled-use ophthalmic tube. Preservative selection becomes more important if the formulation introduces water or an emulsion phase.

Can a manufacturer replace white petrolatum with a different ophthalmic base?

Yes, but the replacement can affect viscosity, drug distribution, ocular tolerability, release and equivalence. A materially different base may require a more extensive comparative development package.

Is hydrocortisone likely to create a separate patent barrier?

For the established combination, hydrocortisone is unlikely to create a meaningful new-chemical patent barrier. Any remaining risk would more likely arise from a specific formulation, dosage form, delivery system or method-of-use claim.

Does a sterile ophthalmic tube create patent protection?

A tube can be covered by device or packaging claims, but packaging alone does not necessarily protect the drug formulation. The commercial value depends on claim scope, patent term, design-around options and whether the device improves dispensing or product stability.

Is a reformulated gel better than a conventional ophthalmic ointment?

Not automatically. A gel may improve spreadability or reduce visual blurring, but it introduces aqueous-phase, preservative, sterility, stability and equivalence challenges. The conventional hydrocarbon ointment remains the lower-risk platform for a generic launch.

References

1. DailyMed. (n.d.). Neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone ophthalmic ointment: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.
3. United States Pharmacopeia. (2024). General chapter <771>: Ophthalmic products. United States Pharmacopeial Convention.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
5. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 200.50: Ophthalmic preparations. FDA.